The study explores the interconnected risks between COVID-19 and Alzheimer’s Disease (AD), highlighting how SARS-CoV-2 can aggravate AD pathology through neuroinflammation and neurodegeneration. It raises significant concerns about the long-term cognitive implications of COVID-19, especially among those already at risk for AD.
CMS postpones national coverage determination for PrEP, says decision is ‘forthcoming’
CMS did not make a national coverage determination for PrEP by the expected date of Oct. 10, but a final decision will be coming later,